Camurati-Engelmann Disease (CED) Cell Models for Research

Camurati-Engelmann Disease (CED) is a rare autosomal dominant disorder with an estimated prevalence of less than 1 in 1,000,000 individuals worldwide (WHO, 2023). It is characterized by progressive hyperostosis of the long bones and skull, leading to bone pain, muscle weakness, and neurological complications. The disease onset typically occurs in childhood, and the severity varies widely. There is no cure, and treatment is symptomatic, focusing on pain management and physical therapy. The chronic nature of CED significantly impacts quality of life, making it a critical area for research into targeted therapies.

CED is an ideal model for studying bone remodeling and TGF-β signaling pathways. The disease is primarily caused by mutations in the TGFB1 gene, which encodes transforming growth factor beta 1. These mutations lead to increased TGF-β activity, resulting in abnormal bone formation. Research on CED can provide insights into the molecular mechanisms of bone homeostasis and offer a platform for testing TGF-β inhibitors. Public datasets, such as those from NCBI ClinVar and UniProt, provide valuable information on TGFB1 mutations and their functional consequences, facilitating the development of gene-edited cell models for drug discovery.

Although CED is not a cancer, its pathogenesis involves dysregulated signaling pathways that are also relevant to cancer biology. The primary pathway is the TGF-β signaling pathway:

1. TGF-β ligand binds to TGF-β receptor type II (TGFBR2).

2. TGFBR2 recruits and phosphorylates TGF-β receptor type I (TGFBR1).

3. Activated TGFBR1 phosphorylates SMAD2 and SMAD3.

4. Phosphorylated SMAD2/3 form a complex with SMAD4.

5. The SMAD complex translocates to the nucleus and regulates target gene transcription.

In CED, mutations in TGFB1 lead to increased TGF-β activity, enhancing SMAD signaling and promoting osteoblast differentiation and bone formation. This pathway is also implicated in fibrosis and cancer progression, making CED a relevant model for studying TGF-β biology.

Data from ClinVar and COSMIC indicate that TGFB1 mutations are the primary cause of CED, with over 20 distinct mutations reported. These mutations are typically located in the latency-associated peptide (LAP) region, leading to premature activation of TGF-β.

The key deregulated signaling network in CED is the TGF-β/SMAD pathway. Key nodes include:

• • TGFB1: Ligand, overexpressed or hyperactive.
• • TGFBR1 and TGFBR2: Receptors, may be altered.
• • SMAD2/3: Transcription factors, hyperphosphorylated.
• • SMAD4: Co-SMAD, essential for nuclear translocation.
• • Target genes: RUNX2, COL1A1, and others involved in osteoblast differentiation.

Additionally, cross-talk with BMP signaling and WNT pathways may modulate the phenotype. These networks provide potential therapeutic targets for CED and related conditions.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) can recapitulate bone development and are useful for studying CED. They offer a more physiologically relevant model than traditional cell lines, allowing for the study of cell-cell interactions and tissue architecture.

Animal models for CED include:

• • Genetically engineered mouse models (GEMMs) carrying TGFB1 mutations (e.g., Tgfb1^C225R) that mimic human CED.
• • Induced models using TGF-β administration to mimic the hyperostosis phenotype.
• • Patient-derived xenografts (PDX) are less common due to the non-cancerous nature of CED, but bone tissue from patients can be transplanted into immunodeficient mice for study.

These models are valuable for studying disease progression and testing therapeutic interventions.

CRISPR-based gene editing has enabled the creation of isogenic cell models for CED. For example:

• • TGFB1 knockout cell lines: These cells lack TGF-β1, allowing researchers to study the loss-of-function effects and the role of TGF-β in bone metabolism.
• • TGFB1 knock-in cell lines: Introduction of specific CED-associated mutations (e.g., R218C) into wild-type cells to model the disease phenotype.

These gene-edited models are sequence-verified and can be used for drug screening and functional studies. Commercially available, these models accelerate research by providing consistent and reproducible systems. However, it is important to validate the genetic modifications and ensure the absence of off-target effects.

Gene-edited cell models are essential for functional genomics studies. For example:

• • TGFB1 knockout cell lines can be used to identify downstream targets of TGF-β signaling through transcriptomic and proteomic analyses.
• • Knock-in cell lines with specific mutations can be compared to wild-type to determine the functional impact of each mutation on cellular phenotype.

These models help validate the role of TGFB1 in bone formation and identify potential therapeutic targets.

Isogenic cell line pairs (wild-type vs. mutant) are powerful tools for drug screening. For CED, these models can be used to:

• • Screen for compounds that inhibit TGF-β signaling, such as TGFBR1 kinase inhibitors.
• • Assess the efficacy of drugs in reducing osteoblast hyperactivity.
• • Study mechanisms of drug resistance by exposing cells to increasing concentrations of inhibitors and selecting for resistant clones.

These approaches can accelerate the development of targeted therapies for CED.

CRISPR-based synthetic lethality screens can identify genes that are essential for the survival of CED cells but not normal cells. This can reveal novel biomarkers and therapeutic targets. For example, screening a library of CRISPR knockouts in TGFB1 mutant cells may identify genes that, when knocked out, selectively kill mutant cells while sparing wild-type cells. These genes could serve as drug targets for CED.